Share on StockTwits

Johnson & Johnson (NYSE:JNJ)‘s stock had its “hold” rating reiterated by research analysts at Deutsche Bank in a report released on Wednesday, Stock Ratings Network.com reports. They currently have a $100.00 price objective on the stock, down from their previous price objective of $102.00. Deutsche Bank’s price target would suggest a potential upside of 0.81% from the stock’s previous close.

The analysts wrote, “Q14 Sales and EPS Beat on Pharma; Maintain Hold. J&J’s sales and EPS were ahead of Consensus, once again driven by outperformance in Pharma. Total sales were up 5.3% ex-FX as growth in Pharma (up 12.2%) was partially offset by MD&D (up 1.8%) and Consumer (down 0.6%). The JNJ investment case remains unchanged. Pharma should continue to drive results, which we believe is well-established and appreciated by the market. We maintain our Hold rating. In volatile markets, we believe JNJ is likely to prove to be a defensive stock.”

Shares of Johnson & Johnson (NYSE:JNJ) remained flat at $99.20 during during mid-day trading trading on Wednesday. 1,775,308 shares of the company’s stock traded hands. Johnson & Johnson has a 52 week low of $82.12 and a 52 week high of $99.38. The stock’s 50-day moving average is $95.20 and its 200-day moving average is $92.83. The company has a market cap of $280.6 billion and a price-to-earnings ratio of 20.63. Johnson & Johnson also saw a large increase in short interest during the month of January. As of March 31st, there was short interest totalling 31,078,666 shares, an increase of 9.6% from the March 14th total of 28,349,984 shares. Based on an average trading volume of 10,166,169 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.1% of the company’s shares are short sold.

Johnson & Johnson (NYSE:JNJ) last released its earnings data on Tuesday, April 15th. The company reported $1.54 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.48 by $0.06. The company had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.00 billion. During the same quarter last year, the company posted $1.44 earnings per share. Johnson & Johnson’s revenue was up 3.5% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post $5.83 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated an “underperform” rating on shares of Johnson & Johnson in a research note on Wednesday. They now have a $100.00 price target on the stock. Separately, analysts at Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday. They now have a $106.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Johnson & Johnson from $104.00 to $106.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $79.14.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.